Indomethacin Cuts RSV in Human Airway Cells at Low Doses, but Only in Early Lab Study
Updated
Updated · Livescience.com · Jun 3
Indomethacin Cuts RSV in Human Airway Cells at Low Doses, but Only in Early Lab Study
3 articles · Updated · Livescience.com · Jun 3
Summary
Virus Research data published May 7 found indomethacin sharply reduced RSV replication in infected human larynx, bronchus and lung cells without harming the cells, pointing to a possible treatment where no RSV antiviral now exists.
The drug worked only after RSV had already entered cells, suggesting it disrupts a protein the virus needs to spread rather than blocking initial attachment or entry.
Aspirin, a similar NSAID, showed no effect on RSV, indicating indomethacin's antiviral action is separate from its pain-relief mechanism.
Doctors not involved in the study said the findings are promising but too preliminary to change care, noting lab results often fail to translate into patients despite indomethacin's prior use in infants and generally safe short-term profile.
RSV remains the top cause of infant hospitalization in the U.S. and a major risk for adults over 65, while current options focus on prevention through vaccines and antibodies rather than treatment after infection.
This drug is already used safely in babies. Could it soon treat RSV too?
Why does one anti-inflammatory stop RSV when a similar one fails?
Indomethacin Reduces RSV Replication by Over 90% In Vitro: A Breakthrough in Antiviral Drug Repurposing
Overview
Indomethacin, a well-known NSAID, has recently shown strong antiviral activity against RSV in laboratory studies. Unlike other NSAIDs, indomethacin works by directly interfering with the virus’s replication machinery, specifically targeting the RNA-dependent RNA polymerase complex. This unique mechanism was highlighted in recent research from 2024 to 2026, where indomethacin reduced RSV viral load by over 90% in human airway cells at clinically relevant doses. These findings set indomethacin apart from similar drugs and reveal its significant potential for drug repurposing, offering hope for new RSV treatments where current options are limited.